Wilson Disease - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Wilson Disease Emerging Therapy and TPP Insights

Thelansis's "Wilson Disease Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Wilson Disease Overview

Wilson disease is an autosomal recessive disorder caused by pathogenic variants in ATP7B, which encodes a copper-transporting ATPase required for biliary copper excretion. Impaired ATP7B function causes copper accumulation in the liver and, with progression, the brain, cornea, and other tissues. Clinical manifestations vary and may include hepatitis, cirrhosis, acute liver failure, tremor, dystonia, dysarthria, movement disorders, psychiatric symptoms, and Kayser-Fleischer rings. Treatment aims to remove excess copper and prevent further accumulation using penicillamine, trientine, and/or zinc. Liver transplantation is reserved for selected patients with acute liver failure or advanced liver disease. Despite effective therapies, lifelong treatment, adherence demands and persistent neurological symptoms remain challenges. These limitations are driving development of disease-modifying strategies, including ATP7B gene replacement and gene-editing approaches such as UX701 and PM577a.

Key Highlights

• In the United States, diagnosed Wilson disease cases are estimated at 7,574 in 2026.
• Wilson disease is a rare inherited disorder that causes copper accumulation in the liver, brain, and other organs.
• Delayed diagnosis can lead to serious hepatic and neurological complications.
• Unmet need remains for treatments that improve copper control and support long-term organ health.

Market Overview

• The Italy Wilson disease market is projected to grow from $25M in 2026 to $33M by 2036.
• Market growth is driven by:
• Continued use of copper-lowering therapies and improved disease management
• Advances in diagnosis and development of novel treatment approaches
• Future growth will depend on therapies that offer effective long-term copper control, improved tolerability, and better patient outcomes.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Lingyi Biotech Co., Ltd.
• Orphalan
• Ultragenyx Pharmaceutical Inc.
• Prime Medicine, Inc.
• Nobelpharma